高トリグリセリド血症(High Triglyceridemia)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
High Triglyceridemia Overview 9
Therapeutics Development 10
Pipeline Products for High Triglyceridemia – Overview 10
Pipeline Products for High Triglyceridemia – Comparative Analysis 11
High Triglyceridemia – Therapeutics under Development by Companies 12
High Triglyceridemia – Therapeutics under Investigation by Universities/Institutes 15
High Triglyceridemia – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
High Triglyceridemia – Products under Development by Companies 19
High Triglyceridemia – Products under Investigation by Universities/Institutes 21
High Triglyceridemia – Companies Involved in Therapeutics Development 22
Acasti Pharma Inc. 22
Actavis plc 23
Alnylam Pharmaceuticals, Inc. 24
Arisaph Pharmaceuticals, Inc. 25
Astellas Pharma Inc. 26
AstraZeneca PLC 27
BASF SE 28
Cardax Pharmaceuticals, Inc. 29
Catabasis Pharmaceuticals, Inc. 30
Essentialis, Inc. 31
Isis Pharmaceuticals, Inc. 32
Jeil Pharmaceutical Co., Ltd. 33
Novartis AG 34
Pharmena SA 35
Poxel SA 36
Tekmira Pharmaceuticals Corp. 37
Thetis Pharmaceuticals LLC 38
High Triglyceridemia – Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
ALN-AC3 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ALN-ANG – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ARI-3037MO – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AS-1708727 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
bezafibrate ER – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BioE-1115 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CAT-2003 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CDX-085 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
diazoxide choline CR – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ISIS-APOCIIIRx – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MAT-9001 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
NKPL-66 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
pradigastat sodium – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
PRC-4016 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecule for Hypertriglyceridaemia – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule to Agonize Farnesoid X Receptor for Metabolic Disorders, Cardiovascular and Gastrointestinal Disorders – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules for Dyslipidemia and Hypertriglyceridemia – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Synthetic Peptides for Dyslipidemic and Vascular Disorders – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
TKM-HTG – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
TP-101 – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
TP-110 – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
TP-252 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
TP-8252 – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
TRIA-662 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
High Triglyceridemia – Recent Pipeline Updates 80
High Triglyceridemia – Dormant Projects 94
High Triglyceridemia – Discontinued Products 95
High Triglyceridemia – Product Development Milestones 96
Featured News & Press Releases 96
Dec 23, 2014: Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission 96
Nov 12, 2014: Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001 97
Nov 10, 2014: Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001 97
Oct 29, 2014: Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001 98
Oct 20, 2014: Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia 99
Sep 30, 2014: Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014 99
Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results 100
Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C 101
Sep 04, 2014: Matinas BioPharma to Present at Three Investor Conferences in September 102
Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014 103
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 105
Disclaimer 105